Clinique Bets on PDRN Skincare Track, High-end Beauty Brands Accelerate Entry into Medical Aesthetics Care Market | Frontline 倩碧押注PDRN护肤赛道，高端美妆品牌加速切入医美护理市场｜最前线

Summary

Clinique has launched the world’s first skincare line centered on recombinant PDRN, signaling that premium beauty brands are accelerating their entry into the medical aesthetics care market.
The consumption trend in medical aesthetics is shifting from one-time procedural experiences to long-term skin management, driving "light medical aesthetics care" and post-procedure repair to become new growth engines for the skincare industry.
The Estée Lauder Companies is strengthening its "scientific skincare" positioning through collaborations with medical institutions and the launch of Class II medical device products, attempting to blur the boundaries between skincare and medical aesthetics.
Ingredients such as PDRN are transitioning from medical applications to daily skincare. The demand for efficacious skincare in China and the younger demographic of medical aesthetics consumers are intensifying this competition.

Deep Analysis

TL;DR

• Clinique has launched the world’s first skincare line centered on recombinant PDRN, signaling that premium beauty brands are accelerating their entry into the medical aesthetics care market.
• The consumption trend in medical aesthetics is shifting from one-time procedural experiences to long-term skin management, driving "light medical aesthetics care" and post-procedure repair to become new growth engines for the skincare industry.
• The Estée Lauder Companies is strengthening its "scientific skincare" positioning through collaborations with medical institutions and the launch of Class II medical device products, attempting to blur the boundaries between skincare and medical aesthetics.
• Ingredients such as PDRN are transitioning from medical applications to daily skincare. The demand for efficacious skincare in China and the younger demographic of medical aesthetics consumers are intensifying this competition.

Why It Matters

This article reveals how beauty giants are addressing bottlenecks in the traditional skincare market by introducing medical-grade ingredients (such as PDRN) and deepening medical-research collaborations, providing strategic reference for the "medicalization of skincare." For industry practitioners, understanding this trend helps grasp the new directions for premium brands in efficacy competition and building consumer trust.

Technical Analysis

• Core Ingredient Innovation: The new CX Skin Source Deep Repair Serum series utilizes recombinant PDRN (Polydeoxyribonucleotide). Estée Lauder claims it is the world’s first skincare product to feature this ingredient as its core component. PDRN, derived from salmon DNA extracts, is traditionally used to promote tissue repair and improve the skin barrier.
• Medical-Research Collaboration Model: The Estée Lauder Companies collaborates with professional institutions such as Jiahui Health to conduct joint research on procedures like AOPT photorejuvenation, radiofrequency microneedling, and Thermage. This explores the application of products in pre- and post-medical aesthetics care scenarios, establishing a clinical verification system.
• Product Matrix Expansion: Beyond its cosmetic lines, Clinique previously launched a recombinant collagen series certified as a Class II medical device in China, specifically for peri-operative skin repair. This creates a complementary product layout combining "cosmetic registration" (妆字号) and "medical device registration" (械字号).

Industry Insights

• Track Integration Trend: The boundaries between skincare and medical aesthetics are increasingly blurring. Brands need to build integrated solutions covering daily care, procedural support, and long-term anti-aging to cater to consumer demand for "post-medical aesthetics management."
• Trust-Building Strategy: International brands must translate medical technology advantages into perceptible product experiences. They should establish credibility through rigorous clinical testing and endorsements from medical channels to compete fiercely against local, Korean, and Japanese brands.
• Opportunities in the Chinese Market: The growing consumer focus on ingredient logic and the younger demographic in medical aesthetics make "efficacious skincare" and "light medical aesthetics care" key incremental markets for premium brands. Targeted efforts in localized R&D and market education are required.

TL;DR

• 倩碧发布全球首款以重组PDRN为核心成分的护肤系列，标志着高端美妆品牌加速切入医美护理市场。
• 医美消费趋势正从单次项目体验转向长期肌肤管理，推动“轻医美护理”及术后修护成为护肤行业新增长点。
• 雅诗兰黛集团通过与医疗机构合作及推出械字号产品，强化“科学护肤”定位，试图模糊护肤与医美的边界。
• PDRN等成分正经历从医疗应用到日常护肤的迁移，中国市场的功效护肤需求及医美年轻化加剧了这一竞争。

为什么值得看

本文揭示了美妆巨头如何通过引入医疗级成分（如PDRN）和深化医研合作来应对传统护肤市场的瓶颈，为行业提供了“护肤医美化”的战略参考。对于从业者而言，理解这一趋势有助于把握高端品牌在功效竞争和消费者信任构建上的新方向。

技术解析

• 核心成分创新：新品CX肌源深修水光系列采用重组PDRN（聚脱氧核糖核苷酸），雅诗兰黛宣称其为全球首款以此为核心成分的护肤品。PDRN源自三文鱼DNA提取物，传统上用于促进组织修复和改善皮肤屏障。
• 医研合作模式：雅诗兰黛集团与嘉会医疗等专业机构合作，针对AOPT光子嫩肤、射频微针、热玛吉等项目进行联合研究，探索产品在医美前后护理场景中的应用，建立临床验证体系。
• 产品矩阵扩展：除了化妆品线，倩碧此前已推出获中国国家二类医疗器械认证的重组胶原蛋白系列，专门用于围术期肌肤修护，形成了“妆字号”与“械字号”互补的产品布局。

行业启示

• 赛道融合趋势：护肤与医美的界限日益模糊，品牌需构建覆盖日常护理、项目辅助及长期抗老的一体化解决方案，以迎合消费者对“医美后管理”的需求。
• 信任构建策略：国际品牌需将医疗技术优势转化为可感知的产品体验，并通过严格的临床测试和医学渠道背书来建立可信度，以应对本土品牌及韩日品牌的激烈竞争。
• 中国市场机遇：中国消费者对成分逻辑的关注度提升及医美人群年轻化，使得“功效护肤”和“轻医美护理”成为高端品牌争夺的关键增量市场，需针对性地加强本土化研发与市场教育。